Fulcrum Therapeutics Inc (FULC) Stock: More Strategic Than Meets the Eye
H.C. Wainwright has recently reduced Fulcrum Therapeutics Inc (FULC) stock to Neutral rating, as announced on September 13, 2024, according to Finviz. Earlier, on September 12, 2024, Stifel had reduced the stock from a Buy to Hold. RBC Capital Mkts also reduced Sector Perform rating with a price target of $4. Additionally, Leerink Partners reduced […]
Fulcrum Therapeutics Inc (FULC) Stock Settles at $3.57: What’s Contributing to This Price Point?
H.C. Wainwright has recently reduced Fulcrum Therapeutics Inc (FULC) stock to Neutral rating, as announced on September 13, 2024, according to Finviz. Earlier, on September 12, 2024, Stifel had reduced the stock from a Buy to Hold. RBC Capital Mkts also reduced Sector Perform rating with a price target of $4. Additionally, Leerink Partners reduced […]
H.C. Wainwright Issues Neutral Rating for Fulcrum Therapeutics Inc (FULC) Stock
H.C. Wainwright has recently reduced Fulcrum Therapeutics Inc (FULC) stock to Neutral rating, as announced on September 13, 2024, according to Finviz. Earlier, on September 12, 2024, Stifel had reduced the stock from a Buy to Hold. RBC Capital Mkts also reduced Sector Perform rating with a price target of $4. Additionally, Leerink Partners reduced […]
Fulcrum Therapeutics Inc (FULC) Posted -24.79% Profit Margin Last Year—Can It Hold Up?
H.C. Wainwright has recently reduced Fulcrum Therapeutics Inc (FULC) stock to Neutral rating, as announced on September 13, 2024, according to Finviz. Earlier, on September 12, 2024, Stifel had reduced the stock from a Buy to Hold. RBC Capital Mkts also reduced Sector Perform rating with a price target of $4. Additionally, Leerink Partners reduced […]
Stifel Just Downgraded Fulcrum Therapeutics Inc (FULC) Stock—What Does This Mean for Investors?
Stifel has recently reduced Fulcrum Therapeutics Inc (FULC) stock to Hold rating, as announced on September 12, 2024, according to Finviz. Earlier, on September 12, 2024, RBC Capital Mkts had reduced the stock from a Outperform to Sector Perform, setting a price target of $4 for FULC stock. Leerink Partners also reduced Market Perform rating […]
Fulcrum Therapeutics Inc (FULC) Stock: More Strategic Than Meets the Eye
Cantor Fitzgerald has recently initiated Fulcrum Therapeutics Inc (FULC) stock to Overweight rating, as announced on May 20, 2024, according to Finviz. Earlier, on March 13, 2024, RBC Capital Mkts had initiated the stock to Outperform, setting a price target of $14. Goldman also initiated Neutral rating with a price target of $5. Additionally, H.C. […]
Why Did Fulcrum Therapeutics Inc (FULC) Stock Tumble -9.14% to $8.85?
Cantor Fitzgerald has recently initiated Fulcrum Therapeutics Inc (FULC) stock to Overweight rating, as announced on May 20, 2024, according to Finviz. Earlier, on March 13, 2024, RBC Capital Mkts had initiated the stock to Outperform, setting a price target of $14. Goldman also initiated Neutral rating with a price target of $5. Additionally, H.C. […]
Fulcrum Therapeutics Inc (FULC) Stock: Understanding Its Underlying Value
Cantor Fitzgerald has recently initiated Fulcrum Therapeutics Inc (FULC) stock to Overweight, as announced on May 20, 2024 according to Finviz. Earlier, on March 13, 2024, RBC Capital Mkts had initiated the stock to Outperform, setting a price target of $14 Goldman also initiated Neutral rating with a price target range from to $5. Additionally, […]
Fulcrum Therapeutics Inc (FULC) Stock Price Reaches $9.24: What Factors Are Influencing This Level?
Cantor Fitzgerald has recently initiated Fulcrum Therapeutics Inc (FULC) stock to Overweight, as announced on May 20, 2024 according to Finviz. Earlier, on March 13, 2024, RBC Capital Mkts had initiated the stock to Outperform, setting a price target of $14 Goldman also initiated Neutral rating with a price target range from to $5. Additionally, […]
Despite the lack of deep value, there is something else: Fulcrum Therapeutics Inc (FULC) Stock
Cantor Fitzgerald raised the price target for the Fulcrum Therapeutics Inc (NASDAQ:FULC) stock to “an Overweight”. The rating was released on May 20, 2024, according to finviz. The research report from Goldman has initiated the stock to Neutral, with a price target set at $5. The stock was upgraded by H.C. Wainwright, who disclosed in […]
